Which are the Top Companies in the Gene-Editing Therapeutics Market?
- CRISPR Therapeutics
- Editas Medicine
- Intellia Therapeutics
- Beam Therapeutics
- Verve Therapeutics
- Sangamo Therapeutics
- Precision BioSciences
- Caribou Biosciences
- Graphite Bio
- Poseida Therapeutics
- Vertex Pharmaceuticals
- Novartis
- Regeneron / Roche / Pfizer
- Homology Medicines / ContraFect / others
- Lonza
- Catalent
- Thermo Fisher Scientific
- WuXi Advanced Therapies / WuXi STA
- Vineti / TrakCel
- Major academic & clinical centers
Market Forecast
The gene editing therapeutics market is rapidly advancing on a global scale, with expectations of accumulating hundreds of millions in revenue between 2025 and 2034. Market forecasts suggest robust development fueled by increased investments, innovation, and rising demand across various industries.
What are the Major Trends in the Gene-Editing Therapeutics Market?
Growing demand for curative therapies: Due to the growing genetic diseases, there is a rise in the demand for curative therapies. Hence, new gene editing therapeutics are being developed. Moreover, to accelerate their development, the number of investments as well as acquisitions is increasing.
For instance,
- In August 2025, to accelerate its development of next-generation treatments for solid tumors, $1 million investment was received by CorriXR Therapeutics, Inc. from the State of Delaware. Moreover, the collaboration between CorriXR and Gene Editing Institute was also highlighted during the funding round, where the company is focusing on advancing CRISPR-based therapies.
- In June 2025, to expand the experimental medicine for long-term growth, Eli Lilly & Co. is planning to acquire Verve Therapeutics Inc., which is a gene-editing biotech firm, for $1.3 billion. For the acquisition of Eli Lilly & Co. will pay $13.50 per share.
Gene-Editing Therapeutics Market Value Chain Analysis
R&D
The R&D of gene editing therapeutics is focusing on developing safe and effective therapies for genetic and other diseases, along with growing advances in technologies like CRISPR, supported by investments.
Key Players: CRISPR Therapeutics, Intellia Therapeutics, Beam Therapeutics, Caribou Biosciences, Editas Medicine
Formulation and Final Dosage Preparation
The formulation and final dosage preparation focus on encapsulating gene-editing components into a delivery vehicle for in vivo or ex vivo administration.
Key Players: Intellia Therapeutics, CRISPR Therapeutics, Moderna Therapeutics, Beam Therapeutics, Prime Medicine
Patient Support and Services
The personalized programs that address the emotional, logistical, and financial challenges of the treatment are involved in the patient support and services of gene-editing therapeutics.
Key Players: Vertex Pharmaceuticals, Bluebird Bio, CRISPR Therapeutics, Novartis Gene Therapies
Latest Announcements by Industry Leaders
In August 2025, after announcing the closing of the seed funding round of Axelyf, its CEO and co-founder, Örn Almarsson, stated that, to tackle the complex diseases, they are developing real solutions and not chasing science fiction. The RNA medicine next chapter will be unlocked with the use of their AXL technology, which offers exceptional performance, the team expertise, and AI-informed capabilities. Thus, this helps in the development of transformative products for them as well as their partners.
What are the Recent Developments in the Gene-Editing Therapeutics Market?
- In March 2025, for the discovery and development of gene editing therapeutics with the use of generative AI (genAI), a collaboration between ElevateBio and Amazon Web Services (AWS) was announced. The gene editing technologies and large clustered regularly interspaced short palindromic repeats (CRISPR) dataset of ElevateBio will be merged with the advanced computing framework of AWS in this collaboration.
- In February 2025, positive results with excellent safety and pharmacodynamics profiles data were announced for an investigator-initiated trial (IIT) of YOLT-203 in patients with primary hyperoxaluria type 1 (PH1), where it also demonstrated potential to normalize urinary oxalate levels in PH1 patients, which was developed by YolTech Therapeutics. The positive clinical data of YOLT-203 represented it as the first in vivo gene-editing therapy for PH1.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
